Insider Transactions in Q1 2025 at Intellia Therapeutics, Inc. (NTLA)
Insider Transaction List (Q1 2025)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 29
2025
|
Muna Bhanji |
SELL
Open market or private sale
|
Direct |
265
-1.34%
|
$2,385
$9.97 P/Share
|
Jan 03
2025
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
26,807
-2.77%
|
$321,684
$12.18 P/Share
|
Jan 03
2025
|
Derek Hicks EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,502
-9.8%
|
$78,024
$12.18 P/Share
|
Jan 03
2025
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,557
-9.83%
|
$114,684
$12.18 P/Share
|
Jan 03
2025
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
7,074
-8.67%
|
$84,888
$12.18 P/Share
|
Jan 03
2025
|
Michael P Dube VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,372
-2.92%
|
$16,464
$12.18 P/Share
|
Jan 03
2025
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,966
-10.38%
|
$107,592
$12.18 P/Share
|
Jan 03
2025
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
7,422
-10.38%
|
$89,064
$12.18 P/Share
|
Jan 02
2025
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
556
-0.77%
|
$6,672
$12.03 P/Share
|
Jan 01
2025
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,850
+0.8%
|
-
|
Jan 01
2025
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+3.9%
|
-
|
Jan 01
2025
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,189
+3.18%
|
-
|